Product logins

Find logins to all Clarivate products below.


Prostate Cancer | Treatment Sequencing | US | 2023

KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand whom to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

  • Where is my product positioned versus competitors in the treatment journey?
  • What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • Where are the untapped business opportunities on which I can capitalize?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?

GEOGRAPHY

United States.

PRIMARY MARKET RESEARCH

Survey of 100 U.S. medical oncologists and urologists.

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.

Related Market Assessment Reports

Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Alzheimer’s Disease – Geographic Focus: China – China In-Depth – Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by cognitive decline, memory impairment, and loss of functional independence. In China, current…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…